Brought to you by 
Novitron acquires Elan Dx, Landmark Scientific
22 May 2003
Executive Summary
Novitron (clinical and analytical scientific instruments) has acquired Elan Diagnostics (clinical instruments and reagents for the physician office laboratory--POL--market) for €6.8mm ($7.5mm) in cash.
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
- Research, Analytical Equipment & Supplies
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novitron acquires Elan Dx, Landmark Scientific
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice